The Other Fish In The Sea: AstraZeneca Buys Omthera
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca agreed to pay $260 million plus contingency payments to acquire Omthera, the makers of the omega-3 product Epanova, which is ready for regulatory filing for dyslipidemia. The deal raises questions for Amarin, whose similar product Vascepa has reached the market without a big pharma partner.
You may also be interested in...
With Venture Cash, Pronutria Mines Food Supply For Drugs And Supplements
Amino acids and protein mixtures are nothing new to bodybuilders and people whose diseases require special diets. The new Flagship company wants to make better cocktails, backed by clinical data.
With Venture Cash, Pronutria Mines Food Supply For Drugs And Supplements
Amino acids and protein mixtures are nothing new to bodybuilders and people whose diseases require special diets. The new Flagship company wants to make better cocktails, backed by clinical data.
AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself
In FibroGen’s FG-4592, AstraZeneca sees a potential strong seller in China where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.